Observe Medical ASA: Innovation Norway financing at NOK 15 million disbursed and dismantling of corporate complexity to further focus on core business

Oslo, 4 March, 2026 - Observe Medical ASA (the "Company" or "Observe Medical") announces initiatives to reduce complexity and cost to invest further in growth.

Innovation Norway financing

The Company has received a NOK 15 million loan from Innovation Norway. The loan has been disbursed and strengthens the Company's cash position and supports continued development of its core business activities and new product development.

Dismantling complexity

As communicated in the interim report announced on 27 February 2026, the Company has fully written down its investment and related book values in respect of the Biim probe due to lack of progress from the Company's key customer. As a consequence, the final steps to close down all Biim related activities have now been resolved by the board including to wind up Biim Ultrasound AS and its subsidiaries.

The decision forms part of the Company's ongoing efforts to streamline its corporate structure and reduce administrative complexity and costs. Following completion of this process the Group structure will be simplified, and our cost base will be reduced accordingly.

As part of the Company's sharpened strategic focus, recruitment of two new commercial resources has been initiated to accelerate market penetration.

CEO Jørgen Mann, comments: "Through reduction of complexity combined with significant cost reduction we are continuing our journey towards building a strong platform with the UnoMeter business where we have seen good progress and a strong Product Development pipeline. With these steps we believe to have completed the right-sizing of Observe Medical and we are now fully focused on accelerating commercial execution and driving growth in our core business."

Observe Medical invites investors, analysts, and other stakeholders to a presentation with trading update 25 March 2026, at 10:00 CET. There we will, among other, focus on our order trajectory inbound 2026, together with the conclusion from our important UnoMeter Safeti Max test that will be finalized by March 20, 2026.

The presentation will be streamed via webcast at the following link: https://qcnl.tv/p/OLaQ0Xa8KdjTtD9W3cv0PQ

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.